Impact of Genetic Polymorphisms at the Promoter area of IL-10 Gene on Tacrolimus Level in Jordanian Renal Transplantation Recipients
Abstract
Background
Tacrolimus is a widely used immunosuppressant that prevents the solid organ transplant rejection. The pharmacokinetics of Tacrolimus show considerable variability. interleukin-10 (IL-10), in the host’s immune response after transplantation contributes to the variable CYP3A-dependent drug disposition of Tacrolimus. In current study, our aim is to evaluate the impact of single nucleotide polymorphisms (SNP) in the promoter region of of IL-10 on Tacrolimus dose requirements and the Dose Adjusted Concentration (DAC) of Tacrolimus among kidney transplantation recipients.
Methods
Blood levels of Tacrolimus were measured using Micorparticle Enzyme Immunoassay (MEIA) for six months post-transplantation. Genotyping analysis was utilized using specific Polymerase Chain Reaction (PCR) followed by sequencing methods for 98 Jordanian kidney transplant recipients.
Results
Genotyping frequencies of IL-10 (-592) were (CC/CA/AA: 38, 46.7, 15.2%); IL-10 (-819) were (CC/CT/TT: 40.4, 44.1, 15.1%); and IL-10 (-1082) were (AA/AG/GG: 42.6, 44.7, 12.8%). The impact of IL-10 (-1082) on Tacrolimus DAC was gender dependent. Men carrying at least one A allele had significantly lower DAC than men carrying GG genotyping only in the first month post-transplantation [88.2±32.1 vs. 117.5±22.5 ng/ml per mg/kg/day, p=0.04]..
Conclusion
Our current study showed that the interaction between gender and IL-10 -1082 affects Tacrolimus DAC in Jordanian kidney transplantation recipients during the first month post-transplantation.
References
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine 2003;139(2):137-47.
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. American Journal of Transplantation 2011;11(10):2093-109.
Magee C, Pascual M. Update in renal transplantation. Archives of internal medicine 2004;164(13):1373-88.
Murray JE, Merrill JP, Harrison JH, Carpenter CB. Renal homotransplantation in identical twins. Journal of the American Society of Nephrology 2001;12(1):201-4.
Sayaideh A, Qaisi S, Asad M. Non-communicable diseases directorate national registry of end stage renal disease (ESRD). www.moh.gov.jo; 2014.
Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010;89(7):851-7.
Siedlecki A, Irish W, Brennan DC. Delayed Graft Function in the Kidney Transplant. American Journal of Transplantation 2011;11(11):2279-96.
Bottomley MJ, Harden PN. Update on the long-term complications of renal transplantation. British Medical Bulletin 2013;106(1):117-34.
Chandran S, Vincenti F. Clinical Aspects: Focusing on Key Unique Organ-Specific Issues of Renal Transplantation. Cold Spring Harbor Perspectives in Medicine 2014;4(2):a015644.
Halloran PF. Immunosuppressive Drugs for Kidney Transplantation. New England Journal of Medicine 2004;351(26):2715-29.
Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplantation proceedings 2004;36(2 Suppl):25S-32S.
Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. British Journal of Clinical Pharmacology 2007;64(6):750-7.
Yousef AM, Qosa H, Bulatova N, Abuhaliema A, Almadhoun H, Khayyat G, et al. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients. Iranian journal of kidney diseases 2016;10(3):156-63.
Gibson AW, Edberg JC, Wu J, Westendorp RGJ, Huizinga TWJ, Kimberly RP. Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus. The Journal of Immunology 2001;166(6):3915-22.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An innvestigation of polymorphism in the Interleukin-10 gene promoter. European Journal of Immunogenetics 1997;24(1):1-8.
Mosser DM, Zhang X. Interleukin‐10: new perspectives on an old cytokine. Immunological reviews 2008;226(1):205-18.
de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Therapeutic drug monitoring 2009;31(4):416-35.
Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clinica chimica acta; international journal of clinical chemistry 2007;383(1-2):133-9.
Scarpelli D, Cardellini M, Andreozzi F, Laratta E, Hribal M, Marini A, et al. Variants of the Interleukin-10 Promoter Gene Are Associated With Obesity and Insulin Resistance but Not Type 2 Diabetes in Caucasian Italian Subjects. Diabetes 2006;55(5):1529-33.
Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Lopez-Rodriguez R, Fernandez-Navarro P, et al. ATA homozigosity in the IL-10gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Medical Genetics 2011;12(1):1-6.
Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003;75(5):711-7.
Yılmaz V, Yentür SP, Saruhan-Direskeneli G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 2005;30(4):188-94.
Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clinical pharmacology and therapeutics 2000;67(1):32-43.
Yousef AM, Qosa H, Bulatova N, Abuhaliema A, Almadhoun H, Khayyat G, et al. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients. Iranian journal of kidney diseases 2016;10(3):156-63.
Zhang X, Wang Z, Fan J, Liu G, Peng Z. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. European journal of clinical pharmacology 2011;67(8):803-13.
Li CJ, Li L, Lin L, Jiang HX, Zhong ZY, Li WM, et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PloS one 2014;9(1):e86206.
Lippi G, Tessitore N, Montagnana M, Bedogna V, Salvagno GL, Targher G, et al. Influence of age and gender variations on glomerular filtration rate estimated by the MCQE formula. Biochemia Medica 2009;19(1):81.
Zhang X, Xu J, Fan J, Zhang T, Li Y, Xie B, et al. Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients. Disease markers 2017;2017:7834035-.
Li C-J, Li L, Lin L, Jiang H-X, Zhong Z-Y, Li W-M, et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PloS one 2014;9(1):e86206-e.
Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clinica chimica acta; international journal of clinical chemistry 2007;383(1-2):133-9.
Copyright (c) 2021 Bara’ah Khaleel, Al-Motassem Yousef, Mazhar AL-Zoubi, Muhammad AL-Ulemat, Ahmad Masadeh, Ali Abuhaliema, Khalid AL-Batayneh, Bahaa Al-Trad
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.